Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTI-808 in Healthy Volunteers and Cystic Fibrosis
NCT03251092Phase 2Completed
- Sponsor
- Proteostasis Therapeutics
- Start
- Jul 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of dirocaftor in cystic fibrosis (CF) (15 arms), sponsored by Proteostasis Therapeutics. Primary endpoints: Adverse Events at 14 days, Physical Exams at 42 days and 9 more. Started Jul 2017; status: completed.
02
Drugs
dirocaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03251092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251092.